NCT04149587View on ClinicalTrials.gov

A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

CompletedOBSERVATIONAL

Enrollment

252

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions

Psoriasis

Interventions

DRUG

Brodalumab

Brodalumab will be administered per dose and schedule specified in the arm.

Trial Locations (11)

Unknown

Bausch Site 009, Nanaimo

Bausch Site 002, Montréal

Bausch Site 001, Winnipeg

Bausch Site 007, Markham

Bausch Site 008, Mississauga

Bausch Site 014, North Bay

Bausch Site 005, Ottawa

Bausch Site 012, Toronto

Bausch Site 010, Waterloo

Bausch Site 011, Drummondville

Bausch Site 003, Surrey

All Listed Sponsors

lead

Bausch Health Americas, Inc.

INDUSTRY

NCT04149587 - A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen | Biotech Hunter | Biotech Hunter